At 9:30 a.m. on August 18, 2020, Huibang Biotech's new product launch conference was held at the Anhui Equity Exchange Center. Nearly 200 leaders and experts from all levels in Anhui, leaders of the national core operation team, strategic investors and the media, etc. Representatives from the field participate.

At the opening of the meeting, Luo Min, deputy director of the management committee, delivered a speech. Deputy director Luo Min said: Huibang Biotechnology has forged ahead for many years, and its solid basic research accumulation has achieved the rapid transformation of scientific and technological achievements. It has successively established three major industrial platforms: an in vitro diagnostic reagent industrialization platform, a medical device manufacturing platform, and a diagnostic monoclonal antibody research and development center. In recent years, the life and health industry is becoming a new engine for the development of modern economy in Hefei High-tech Zone. In 2020, the life and health industry in the high-tech zone will actively invest in the research and development and production of new crown pneumonia-related products during the epidemic. With the rise of a group of advantageous enterprises such as Huibang Biotechnology, the development of new economic industries in Hefei will be further strengthened. The construction of the high-tech zone The pace of world-class high-tech parks will be further accelerated.

Luo Min, Deputy Director of the Management Committee

Wang Zhongliang, Chairman of Huibang Biology, delivered a speech

Professor Yang Jinkui, Director of Beijing Tongren Hospital Affiliated to Capital Medical University/Beijing Institute of Diabetes, deciphered the "Non-invasive Diabetic Kidney Disease Detection System" at the press conference

Extract a drop of urine and get results in 10 minutes

The non-invasive detection system for diabetic nephropathy launched by Huibang Biotechnology ; it will benefit 3 billion people in the next 5 years

Diabetic nephropathy is a common complication of diabetes, and its prevalence rate is about 40%. However, the only conventional detection method is puncture, which brings pain and inconvenience to patients. Anhui Huibang Bioengineering Co., Ltd. (hereinafter referred to as Huibang Biotechnology) developed the "Type II Diabetic Kidney Disease Noninvasive Detection System" which only needs to extract a drop of urine, and the test result can be obtained in 10 minutes. The system is composed of "dry urine analyzer" and "heptohaptoglobin/urine microalbumin/creatinine detection kit", among which the detection of urine haptoglobin is the first in the world, which solves the problem of early stage kidney damage in type Ⅱ diabetes at home and abroad. Difficulties and pain points of diagnosis.

According to the latest global diabetes map released by the International Diabetes Federation, there are 463 million people with diabetes in the world in 2019, and it will reach 578 million in 2030. Among them, my country's diabetic patients rank first in the world, with 116.4 million people, and will reach 140.5 million in 2030. The potential patient market in China exceeds 200 million person-times.

Diabetic kidney disease (DKD) is a common complication of diabetes, with a prevalence of about 40%. It is the most common cause of end-stage renal disease (dialysis). Only by early detection and early intervention can it be prevented before it happens.

Before the appearance of this product, the current diagnostic method for DKD was only renal puncture, but because of its high degree of invasiveness, pain, and risk of infection, routine testing is not recommended; "urine microalbumin/creatinine ratio ( ACR)" is widely used, but it is not specific for DKD, and its level is affected by many factors, the detection rate of type Ⅱ diabetic nephropathy is not high, and there are limitations in predicting the outcome of the disease. The new detection method "Non-invasive Detection System for Type 2 Diabetic Nephropathy" launched by Huibang Biotech can get the detection result within 10 minutes with just a drop of urine from the patient.

Professor Yang Jinkui, director of Beijing Tongren Hospital Affiliated to Capital Medical University/Beijing Institute of Diabetes, introduced in an interview with a TV reporter: "The non-invasive detection system for diabetic nephropathy" uses "urine haptoglobin" as an early marker of impaired renal function in diabetic patients , its level changes earlier than urinary microalbumin, which can make up for the deficiency of urinary microalbumin.

The products launched by Huibang Biotechnology this time have the advantages of system design based on diagnostic standards, dry "non-invasive" detection mode that is convenient for storage and transportation, and independent research and development of key raw material monoclonal antibodies. The combined innovative biochemical immune detection platform is simple, fast, precise features. For the market, the above-mentioned 110 million people with diabetes in China are just in demand. At the same time, a large number of hidden patients will be found in the physical examination of normal people, which can effectively reduce the expenditure of national chronic disease funds. On July 15, 2019, the State Council issued the "Opinions of the State Council on the Implementation of Healthy China Action", which is an important document at the national level to guide future disease prevention and health promotion work. The "Opinions" proposes 15 main tasks, of which Article 14 specifically emphasizes that my country is one of the countries with the fastest-growing prevalence of diabetes, strengthen the health management of diabetic patients and high-risk groups, and focus on promoting the screening of diabetes and complications at the grassroots level. Standardization of examination and standardization of diagnosis and treatment. By 2022 and 2023, the standard management rate of diabetes patients will reach 60% and above and 70% or above, respectively. The launch of the "Non-invasive Diabetic Kidney Disease Detection System" is in line with the national policy and needs.

The product technology launched by Huibang Biotechnology involves the key raw materials of monoclonal antibodies, all of which are independently researched and developed. Among them, the haptoglobin dry immunoassay technology is the first at home and abroad. It obtained the national invention patent in 2018 and has completely independent intellectual property rights; The developed dry urine analysis instrument is sensitive, accurate and stable, and integrates biochemical and immunological methodologies. There is no similar product in the market. Experts estimate that this technology will benefit nearly 3 billion tests in the next five years.